FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis

Annals of Pharmacotherapy - Tập 36 Số 2 - Trang 288-295 - 2002
Mohamed A. Omar1,2, James P. Wilson3
1Mohamed A Omar MSc PhD, at time of writing, PhD candidate, Division of Pharmacy Practice and Administration, College of Pharmacy, University of Texas at Austin, Austin, TX; now, Outcomes Research Manager, HealthCare Management, Novartis Pharmaceuticals Corporation, East Hanover, NJ
2now, Outcomes Research Manager, HealthCare Management, Novartis Pharmaceuticals Corporation, East Hanover, NJ
3James P Wilson PharmD PhD, Associate Professor, Division of Pharmacy Practice and Administration, College of Pharmacy, University of Texas at Austin

Tóm tắt

OBJECTIVE: To determine the number of cases of statin-associated rhabdomyolysis reported to the Food and Drug Administration for 6 statins and to profile the cases. METHODS: A retrospective analysis of all domestic and foreign reports of statin-associated rhabdomyolysis between November 1997 and March 2000 was conducted. Outcome measures included the total number of reports (initial plus follow-up), the number of unique cases, age, gender, percentages of report codes and role codes, and frequencies of concomitant interacting drugs that may have precipitated rhabdomyolysis, outcomes codes, and report source codes. RESULTS: There were 871 reports of statin-associated rhabdomyolysis in the 29-month time frame examined, representing 601 cases. The following number of cases were associated with each of the individual statins: simvastatin, 215 (35.8%); cerivastatin, 192 (31.9%); atorvastatin, 73 (12.2%); pravastatin, 71 (11.8%); lovastatin, 40 (6.7%); and fluvastatin, 10 (1.7%). Drugs that may have interacted with the statins were present in the following number of cases: mibefradil (n = 99), fibrates (n = 80), cyclosporine (n = 51), macrolide antibiotics (n = 42), warfarin (n = 33), digoxin (n = 26), and azole antifungals (n = 12). The reports of 62.1% of cases were classified as expedited. Statins were designated as the primary suspect in 72.0% of the cases. Death was listed as the outcome in 38 cases. The majority of reports (n = 556) were from health professionals. CONCLUSIONS: Compared with the other statins, simvastatin and cerivastatin were implicated in a relatively higher number of reports. Because of the various limitations of a spontaneous reporting-system database, caution is urged when interpreting the relative number of cases reported.

Từ khóa


Tài liệu tham khảo

Goldman SA, 1995, MedWatch continuing education article. Clinical therapeutics and the recognition of drug-induced disease

MedWatch continuing education article. The clinical impact of adverse event reporting. Staff College, Center for Drug Evaluation and Research, Food and Drug Administration, October 1996. Available from: URL: http://www.fda.gov/medwatch/articles/med.pdf.

Burke LB, 1998, Pharmacoepidemiology: An introduction, 3, 213

10.1002/pds.594

FDA talk paper. June 8, 1998. Roche Laboratories announces withdrawal of Posicor from the market [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00876.html.

FDA talk paper. February 27, 1998. Seldane and generic terfenadine withdrawn from market [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00853.html.

FDA talk paper. June 21, 1999. Janssen Pharmaceutica announces the withdrawal of Hismanal from the market [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00961.html.

FDA talk paper. March 23, 2000. Janssen Pharmaceutica stops marketing cisapride in the US [cited 2001 Sep 203. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS01007.html.

FDA talk paper. August 8, 2001. Bayer voluntarily withdraws Baycol [cited 2001 Sep 20]. Available from: URL: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01095.html.

10.1001/jama.279.20.1615

10.1016/S0002-9149(97)00346-9

10.1056/NEJM199811053391902

10.1161/01.CIR.91.10.2528

Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383

Illingworth DR, 1994, Clin Ther, 16, 366

10.2165/00002018-199614010-00003

10.2165/00002018-199106020-00003

10.1177/106002809502907-818

10.1016/0002-9149(94)90626-2

Herman R, 1999, Can Med Assoc J, 161, 1281

10.1016/S0002-9343(89)80597-2

10.1159/000174683

10.1161/01.CIR.101.2.207

10.1093/ajhp/52.15.1639

10.1159/000186289

10.1016/0303-8467(93)90122-W

Dayer-Berenson L, 1994, ANNA J, 21, 15

Prescription drug expenditures in 2000: the upward trend continues. A report by the National Institute for Health Care Management Research and Educational Foundation. May 2001 [cited 2001 Sep 20]. Available from: URL: http://www.nihcm.org.

10.1345/aph.10228

10.1345/aph.10315

10.1001/jama.1990.03450010075034

Sweetman S, 2001, Martindale: the complete drug reference

10.1177/106002808702101216

Weber JCP, 1984, Advances in inflammation research. Vol 6, 1

10.1111/j.1365-2125.1994.tb04373.x

Thông tin
Thông tin xuất bản

Annals of Pharmacotherapy

Tập 36 Số 2

288-295

Thông tin tác giả